top of page

March 15-16 2024

EULAR/PReS Recommendations for the management of Adult-onset Still’s disease and systemic JIA

In the ever-evolving landscape of rheumatology, an exclusive interview between two distinguished experts, Professor Fabrizio De Benedetti and Professor Bruno Fautrel, unveils the highly anticipated recommendations for the management of Adult-onset Still’s disease (AOSD) and systemic Juvenile Idiopathic Arthritis (sJIA).





  1. The Need for Recommendations: The interview commences with an exploration of the critical necessity for comprehensive guidelines in managing Adult-onset Still’s disease and systemic Juvenile Idiopathic Arthritis. Professors De Benedetti and Fautrel shed light on the challenges faced by healthcare professionals and patients alike, emphasizing the urgency for standardized recommendations to guide effective treatment strategies.

  2. How Did They Do It? Our experts provides a behind-the-scenes glimpse into the extensive research, expert consensus, and collaborative endeavors that went into crafting these influential recommendations.

  3. AOSD and sJIA: One Unified Disease: The third segment draw parallels between Adult-onset Still’s disease and systemic Juvenile Idiopathic Arthritis, revealing the compelling argument that these conditions are not isolated entities but rather manifestations of one unified disease.

  4. Disease Remission and Prompt Strategies: Delving into the core of disease management, Professors De Benedetti and Fautrel discuss the crucial topic of disease remission and strategies to achieve it promptly.

  5. Treatment Algorithm and Rapid Steroid Weaning: The interview progresses to highlight the treatment algorithm, with a particular focus on the rapid weaning of steroids. Our experts underscore the significance of minimizing steroid use and present a comprehensive approach to achieving optimal outcomes in patients with AOSD and sJIA.

  6. Early Use of Biologics: A Paradigm Shift: A key message surfaces as Professors De Benedetti and Fautrel advocate for a paradigm shift in the early use of biologics. Specifically, they emphasize that IL-1 or IL-6 inhibitors should be administered as soon as the diagnosis of Still's disease is made, presenting a groundbreaking approach to treatment.

  7. Difficult to Treat Patients: A Major Concern: As the interview concludes, the experts acknowledge the challenges that persist in treating Still's disease, paving the way for future research and advancements in the field.

Conclusion: This exclusive interview provides a comprehensive overview of the forthcoming recommendations for the management of Adult-onset Still’s disease and systemic Juvenile Idiopathic Arthritis. Professors De Benedetti and Fautrel's insights promise to reshape the landscape of rheumatology, offering new hope and strategies for both healthcare professionals and patients alike.


This interview was conducted by Charlotte Girard-Guyonvarc'h - JIR CliPS - WG sJIA/AOSD under the COST Association - European Cooperation in Science and Technology.

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. https://www.cost.eu/actions/CA21168/

Subscribe to our Newsletter and stay informed!

bottom of page